Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials

PLoS Medicine

Volumn 6, Issue 5, 2009, Pages

  Sarzotti Kelsoe, Marcella ^a   Cox, Josephine ^b   Cleland, Naana ^c   Denny, Thomas ^d   Hural, John ^e   Needham, Leila ^a,d   Ozaki, Daniel ^a   Rodriguez Chavez, Isaac R ^c,i   Stevens, Gwynneth ^f   Stiles, Timothy ^g   Tarragona Fiol, Tony ^f   Simkins, Anita ^h  

^a DUKE UNIVERSITY   (United States)

^b International AIDS Vaccine Initiative   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HIV Vaccine Trials Network   (United States)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g Qualogy Ltd   (United Kingdom)

^h AlphaVax Inc   (United States)

ⁱ NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL LABORATORY; CLINICAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; LABORATORY DIAGNOSIS; PRACTICE GUIDELINE; SHORT SURVEY;

CLINICAL LABORATORY TECHNIQUES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 66349102222     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000067     Document Type: Short Survey

References (26)

1. Code of Federal Regulations (2005) 21 CFR Part 58. Good laboratory practice for nonclinical laboratory studies. Available: http://www.access.gpo. gov/nara/cfr/waisidx-05/21cfr58-05.html. Accessed 31 March 2009.
2. Code of Federal Regulations (2005) 42 CFR Part 493. Laboratory requirements. Available: http://www.access.gpo.gov/nara/cfr/waisidx-05/42cfr493- 05.html. Accessed 31 March 2009.
3. College of American Pathologists (2009) Surveys and anatomic pathology education programs. Available: http://www.cap.org/apps/cap.portal?-nfpb= true&-pageLabel=education. Accessed 31 March 2009.
4. International Organization for Standardization (2003) ISO 15189: Medical laboratories - Particular requirements for quality and competence. Available: http://www.iso.org/iso/en/CatalogueDetailPage.CatalogueDetail?CSNUMBER=26301. Accessed 31 March 2009.
5. European Medicines Agency (1996) ICH topic E6 guideline for good clinical practice. Step 5, consolidated guideline. CPMP/ICH/135/95. Available: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf. Accessed 6 April 2009.
6. Stiles T, Grant V, Mawbey N (2003) Good clinical laboratory practice (GCLP): A quality system for laboratories which undertake the analyses of samples from clinical trials. Ipswich (UK): British Association of Research Quality Assurance. pp 1-17. ISBN 1-904610-00-5.
7. Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, et al. (2008) Guidelines on good clinical laboratory practice: Bridging operations between research and clinical research laboratories. J Pharm Biomed Anal 46: 18-29. (Pubitemid 350216340)
8. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, et al. (2003) The need for a global HIV vaccine enterprise. Science 300: 2036-2039. (Pubitemid 36760117)
9. Stevens W (2003) Good clinical laboratory practice (GCLP): The need for a hybrid of good laboratory practice and good clinical practice guidelines/ standards for medical testing laboratories conducting clinical trials in developing countries. Qual Assur 10: 83-89.
10. Gilmour JW, Stevens W, Gray C, De Souza M (2007) Laboratory expansion to large-scale international HIV preventive vaccine trials. Curr Opin HIV AIDS 2: 201-206. (Pubitemid 46941118)
11. International Conference on Harmonisation (1995) Guideline for industry: Text on validation of analytical procedures. ICH-Q2A: 1-4. Available: http://www.fda.gov/cder/Guidance/ichq2a.pdf. Accessed 31 March 2009.
12. ICH Tripartite Guideline (2005) Validation of analytical procedures: Text and methodology. Q2(R1): 1-13. Available: http://www.ich.org/cache/compo/276- 254-1.html. Accessed 6 April 2009.
13. Thomas SJ, Hombach J, Barrett A (2009) Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 27: 355-368.
14. D'Souza P, Cox JH, Ferrari G, Thapa Kunwar N, Polonis V, et al. (2008) Endpoint assays in HIV-1 vaccine trials: Functioning in a good laboratory practices environment. In: Prabhakar U, Kelley M, eds. Validation of cell-based assays in the GLP setting: A practical guide. Chichester (UK): John Wiley. pp 239-275.
15. Sarzotti-Kelsoe M (2007) Regional chapter news: NCCSQA GCLP workshop review. Qual Matters 23: 13.
16. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323: 39-54. (Pubitemid 46722712)
17. Landay AL, Fleischer TA, Kuus-Reichel K, Maino VC, Reinsmoen N, et al. (2004) Performance of single cell immune response assays: Approved guideline. Clinical and Laboratory Standards Institute 24: 1-71.
18. Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, et al. (2008) Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 9: 9.
19. Xu Y, Theobald V, Sung C, DePalma K, Atwater L, et al. (2008) Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J Transl Med 6: 61. doi:10.1186/1479-5876-6- 61.
20. Tholen DW, Berte LM, Cooper WG, Gun-Munro J, Noble MA, et al. (2007) Using proficiency testing to improve the clinical laboratory: Approved guideline-Second edition. Clinical Laboratory Standards Institute 27: 1-41.
21. Cox JH, Ferrari G, Kalams S, Lopaczynski W, Oden N, et al. (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21: 68-81. (Pubitemid 40179803)
22. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, et al. (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57: 303-315. (Pubitemid 350295382)
23. Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, et al. (2009) Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol 16: 147-155.
24. Sarzotti-Kelsoe M, Ozaki DA, Greene K, Rodriguez-Chavez IR, Ahlers J, et al. (2007) Establishing an international proficiency testing program for anti-HIV-1 neutralizing antibody assay. Qual Assur J 11: 46-47.
25. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A (2008) Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother 57: 285-288.
26. Disis ML (2004) Assay validation for vaccine potency assessment [presentation]. Immune Monitoring Workshop II; 4 November 2004; San Francisco, CA, United States. Available: http://www.isbtc.org/meetings/am04/workshop- presentations/disis.pdf. Accessed 31 March 2009.